Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-21

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Menu

    Tirasemtiv

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 1005491-05-3, Ck-2017357, Tirasemtiv(ck-2017357), 6-ethynyl-1-(pentan-3-yl)-1h-imidazo[4,5-b]pyrazin-2-ol, 5-ethynyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one, Ck2017357
    Molecular Formula
    C12H14N4O
    Molecular Weight
    230.27  g/mol
    InChI Key
    RSQGZEAXODVTOL-UHFFFAOYSA-N
    FDA UNII
    G8WSM7R635
    Tirasemtiv has been used in trials studying the treatment of Myasthenia Gravis, Intermittent Claudication, and Amyotrophic Lateral Sclerosis.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    5-ethynyl-3-pentan-3-yl-1H-imidazo[4,5-b]pyrazin-2-one
    2.1.2 InChI
    InChI=1S/C12H14N4O/c1-4-8-7-13-10-11(14-8)16(12(17)15-10)9(5-2)6-3/h1,7,9H,5-6H2,2-3H3,(H,13,15,17)
    2.1.3 InChI Key
    RSQGZEAXODVTOL-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CCC(CC)N1C2=NC(=CN=C2NC1=O)C#C
    2.2 Other Identifiers
    2.2.1 UNII
    G8WSM7R635
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Ck-2017357

    2.3.2 Depositor-Supplied Synonyms

    1. 1005491-05-3

    2. Ck-2017357

    3. Tirasemtiv(ck-2017357)

    4. 6-ethynyl-1-(pentan-3-yl)-1h-imidazo[4,5-b]pyrazin-2-ol

    5. 5-ethynyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one

    6. Ck2017357

    7. G8wsm7r635

    8. 6-ethynyl-1-(pentan-3-yl)-2h-imidazo(4,5-b)pyrazin-2-one

    9. 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-2h-imidazo(4,5-b)pyrazin-2-one

    10. 2h-imidazo(4,5-b)pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-

    11. 2h-imidazo[4,5-b]pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-;2h-imidazo[4,5-b]pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-

    12. Tirasemtiv [inn]

    13. Tirasemtiv (usan/inn)

    14. Tirasemtiv [usan:inn]

    15. Unii-g8wsm7r635

    16. Ck 2017357

    17. 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-2h-imidazo[4,5-b]pyrazin-2-one

    18. Tirasemtiv (ck-2017357)

    19. Tirasemtiv [usan]

    20. Tirasemtiv [who-dd]

    21. Schembl976988

    22. Gtpl8280

    23. Chembl3039529

    24. Dtxsid90143379

    25. Ex-a367

    26. Bcp27991

    27. Bdbm50316148

    28. Mfcd28023588

    29. Zinc95627912

    30. Akos027250724

    31. Db12209

    32. Sb16955

    33. Ncgc00378555-02

    34. Ac-35962

    35. Bs-22417

    36. Da-48425

    37. Hy-15964

    38. Ft-0746303

    39. S0196

    40. D10327

    41. A898831

    42. Q27088998

    43. Ck2017357; Ck-2017357; Ck 2017357

    44. 6-ethynyl-1-(pentan-3-yl)-1h-imidazo[4,5-b]pyrazin-2(3h)-one

    45. 6-ethynyl-1-(pentan-3-yl)-1,3-dihydro-2h-imidazo[4,5-b]pyrazin-2-one

    46. W97

    2.4 Create Date
    2008-02-19
    3 Chemical and Physical Properties
    Molecular Weight 230.27 g/mol
    Molecular Formula C12H14N4O
    XLogP31.4
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count3
    Rotatable Bond Count4
    Exact Mass230.11676108 g/mol
    Monoisotopic Mass230.11676108 g/mol
    Topological Polar Surface Area58.1 Ų
    Heavy Atom Count17
    Formal Charge0
    Complexity344
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of amyotrophic lateral sclerosis